Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 15 04:00PM ET
2.00
Dollar change
-0.03
Percentage change
-1.48
%
Index- P/E- EPS (ttm)-0.27 Insider Own59.01% Shs Outstand11.53M Perf Week-4.31%
Market Cap23.08M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.73M Perf Month0.02%
Income-3.08M PEG- EPS next Q-0.04 Inst Own0.00% Short Float0.83% Perf Quarter-1.96%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio8.93 Perf Half Y-54.85%
Book/sh0.74 P/B2.70 EPS next Y- ROA-46.37% Short Interest0.04M Perf Year-38.84%
Cash/sh0.59 P/C3.38 EPS next 5Y- ROE-68.68% 52W Range1.89 - 5.75 Perf YTD-59.18%
Dividend Est.- P/FCF- EPS past 5Y- ROI-34.84% 52W High-65.22% Beta0.63
Dividend TTM- Quick Ratio14.08 Sales past 5Y0.00% Gross Margin- 52W Low5.82% ATR (14)0.10
Dividend Ex-Date- Current Ratio14.08 EPS Y/Y TTM-90.04% Oper. Margin0.00% RSI (14)46.33 Volatility7.26% 3.89%
Employees34 Debt/Eq0.04 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price5.00
Option/ShortNo / Yes LT Debt/Eq0.04 EPS Q/Q9.49% Payout- Rel Volume0.57 Prev Close2.03
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMay 29 Avg Volume4.39K Price2.00
SMA20-1.71% SMA50-3.38% SMA200-31.73% Trades Volume2,484 Change-1.48%
Mar-20-24 08:30AM
Mar-18-24 06:00AM
Mar-04-24 05:00AM
Jan-29-24 07:00AM
Dec-05-23 07:30AM
09:21AM Loading…
Nov-17-23 09:21AM
Nov-14-23 07:47AM
Oct-24-23 01:00PM
Sep-25-23 07:00AM
Aug-29-23 09:00AM
Aug-17-23 07:30AM
Aug-15-23 01:00PM
Aug-01-23 07:00AM
Jul-27-23 09:00AM
Jul-14-23 10:52AM
07:00AM Loading…
Jul-06-23 07:00AM
Jun-28-23 09:00AM
May-11-23 09:00AM
May-09-23 10:07AM
Apr-13-23 08:00PM
CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. It operates through the Malaysia and Singapore geographical segments. The company was founded by Chee Kong Choo on March 9, 2018 and is headquartered in Singapore.